Oral News and Research

RSS

Tianyin Pharmaceutical reports 40.2% increase in revenues for the first quarter of fiscal 2010

Tianyin Pharmaceutical Co., Inc., a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced fiscal results for its first quarter ended September 30, 2009.

13 Nov 2009

Rural thoughts on improving the health care system; plus other state news

Kaiser Health News examines rural health care in Kentucky and finds that models for community health care that operate there could benefit the nation's health care system despite. The article notes that Hazard, Ky., was labeled as one of the worst health care regions in America by the 2008 American Human Development Report, but "there are enduring models in places like Hazard that could prove instructive to rebuilding healthy communities across the nation, both rural and urban."

13 Nov 2009

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

13 Nov 2009

Third quarter 2009 financial results announced by Soligenix

Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today its financial results for the third quarter of 2009.

13 Nov 2009

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Pharmacyclics, Inc. today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.

13 Nov 2009

Root canal treatment: Pennsylvania Dental Association answers patients' questions

You're visiting the dentist for what you think is a routine checkup and cleaning when he or she says you need a root canal. Though it's a term you've probably heard before, now that you're the one in the chair, you may have several questions and feel apprehensive about your upcoming procedure.

13 Nov 2009

Medtronic launches an educational campaign to raise awareness of overactive bladder

Medtronic, Inc. today announced the kick-off of an educational campaign aimed at raising awareness among women of overactive bladder (OAB), a serious condition that can severely impact patients’ lives. This new campaign, conducted in partnership with leading patient advocacy groups focused on women’s health will help to raise awareness of the prevalence of bladder control problems and encourage patients to find effective treatment options – including and beyond medications.

13 Nov 2009

Health Canada approves ONGLYZA for type 2 diabetes treatment

Bristol-Myers Squibb Canada and AstraZeneca Canada today announced that Health Canada has approved ONGLYZA(TM) (saxagliptin) which improves all three key measures of glycemic control - hemoglobin A1c (A1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG) - when taken in combination with other commonly used oral anti-diabetic agents (metformin or a sulfonylurea).

13 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Mouth: A diagnostic indicator for general health

The mouth or oral cavity area is an excellent indicator of the whole body's health, says Mao, who is the chair of the new Department of Oncology and Diagnostic Sciences at the School.

13 Nov 2009

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.

13 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

ARYx Therapeutics announces operating results for the third quarter of 2009

ARYx Therapeutics, Inc. today reported results of operations and provided a general business update for the third quarter ended September 30, 2009.

12 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has announced that two of its studies regarding its application in oncology drug development and personalized medicine have been selected for a poster and oral presentation at the upcoming AACR-EORTC conference in Boston.

12 Nov 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.

12 Nov 2009

A discreet option for pain relief in the workplace

Employers say that back pain-related problems account for over 100 million lost workdays a year. In a cutthroat economy with unemployment at a record high, this is especially disconcerting news. Employees cannot afford to risk losing their jobs to other candidates while stuck home in bed recuperating. With 80% of Americans experiencing back pain in their lifetime, back issues have serious implications on job security and can negatively affect even the most dedicated employee’s performance abilities and job attendance.

12 Nov 2009

Medical Marijuana completes weekend Educational Seminar in Ukiah, California

Medical Marijuana Inc (PINKSHEETS: MJNA) completed its initial two day weekend Educational Seminar held Saturday and Sunday November 7 and 8 in Ukiah, CA.

12 Nov 2009

On-line journal Diabetic Hypoglycemia calls for greater understanding and taking control of diabetes

The on-line journal Diabetic Hypoglycemia (http://www.hypodiab.com/) supports the message of World Diabetes Day 2009 (http://www.worlddiabetesday.org) in their call for greater understanding and taking control of diabetes.

12 Nov 2009

Oral News and Research

Tianyin Pharmaceutical reports 40.2% increase in revenues for the first quarter of fiscal 2010

Rural thoughts on improving the health care system; plus other state news

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Third quarter 2009 financial results announced by Soligenix

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Root canal treatment: Pennsylvania Dental Association answers patients' questions

Medtronic launches an educational campaign to raise awareness of overactive bladder

Health Canada approves ONGLYZA for type 2 diabetes treatment

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mouth: A diagnostic indicator for general health

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

ARYx Therapeutics announces operating results for the third quarter of 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Predictive power of Champions Biotechnology's Biomerk Tumorgraft platform to be presented

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

A discreet option for pain relief in the workplace

Medical Marijuana completes weekend Educational Seminar in Ukiah, California

On-line journal Diabetic Hypoglycemia calls for greater understanding and taking control of diabetes

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News